NCT06164756
Long Term Follow Up KET-PD
Enrolling by Invitation
Not specifiedAges 40–80ObservationalYale UniversityInvestigator-initiated
~40 participants
Updated 2025-07-11 on ClinicalTrials.gov
What's tested:Cognitive Behavior Therapy (CBT)Treatment As Usual (TAU)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-Term Change in Depression Severity
Measured over 3 Months and 6 Months
Conditions
Where it's being run
1 sites across 1 statesConnecticut1
Study leadership
- Sophie E. Holmes, PhD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Long-Term Change in Depression Severity3 Months and 6 Months
Change in MADRS score following course of ketamine vs. placebo treatment at 3 and 6 month timepoints; and change in MADRS across treatment (ketamine/placebo) and follow-up (CBT/TAU) arms at 3 and 6 month timepoints. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression.